Navigation Links
In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
Date:12/16/2009

WALTHAM, Mass., Dec. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, according to responses from surveyed dermatologists, Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab (both interleukin inhibitors) will capture 22 percent of the biologics share in 2012 in the drug market for moderate to severe psoriasis. Among these two agents, Stelara will experience greater uptake, capturing nearly three times as much patient share as briakinumab.

The new Physician & Payer Forum report entitled The Next Wave of Psoriasis Biologics: Physician and Payer Perspectives on Novel Interleukin Inhibitors finds that, among the currently-available TNF-alpha inhibitors, Amgen/Pfizer/Takeda's Enbrel--the most-prescribed biologic in psoriasis--will lose the greatest percentage of sales as a result of Stelara's uptake. By the end of 2012, surveyed physicians expect to use Stelara in 16 percent of biologics-treated patients with moderate to severe psoriasis. Additionally, Abbott/Eisai's TNF-alpha inhibitor Humira will also lose substantial market share to Stelara. However, the report finds that other biologics such as Centocor Ortho Biotech/Merck/Mitsubishi Tanabe's Remicade (a TNF-alpha inhibitor) and Astellas's Amevive (a T-cell modulator) are expected to preserve their limited market share, owing to their status as niche therapies.

"Currently, biologic treatment for psoriasis is overwhelmingly dominated by Enbrel, Humira and Remicade as these agents have proved effective and, after years of marketing, physicians' concerns about the long-term safety of these drugs have eased somewhat," said Decision Resources Analyst Joanna Kim, M.Ed. "However, the landscape for biologic therapies in psoriasis experienced a noteworthy shift when Genentech/Merck Serono's T-cell modulator Raptiva was withdrawn from the market
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
2. Calorimeters and Thermal Analysis Equipment Market to Exceed $539 Million by 2012, According to New Report by Global Industry Analysts
3. Cell/Tissue Culture Supplies Market to Reach $4.97 Billion by 2012, According to New Report by Global Industry Analysts
4. Global Agricultural and Environmental Diagnostics Market to Reach $2.4 Billion by 2012, According to New Report by Global Industry Analysts
5. Global Drug Discovery Technologies Market to Exceed $57 Billion by 2012, According to a New Report by Global Industry Analysts
6. Laboratory Pumping Systems to Reach $3.1 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
7. New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
8. Elusive hot electrons captured in ultra-thin solar cells
9. Impact of Open Source Software on Clinical Trials Grows With Release of OpenClinica 3.0 Electronic Data Capture Software
10. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
11. Single-molecule technique captures calcium sensor calmodulin in action
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... Grenoble, France and Dallas, TX, USA (PRWEB) , ... ... ... manufacturer of innovative nano and microsystems, has appointed Francois Vieillard as Sales & ... & Marketing at executive positions, Francois Vieillard will be responsible for reinforcing Tronics’ ...
(Date:7/30/2015)... Washington , July 30, 2015 ... Market, by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial ... Discovery & Development, Preclinical, Clinical Trial), by End Users ... Biosimulation Market is expected to reach USD 2,107.99 million ... a CAGR of 15.29%. Browse more ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Tronics appoints Francois Vieillard as Sales and Marketing Director 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... for Biologically Inspired Engineering at Harvard University have developed ... seek out specific cell targets within a complex mixture ... as telling cancer cells to self-destruct. Inspired by the ... might one day be used to program immune responses ...
... ORLANDO, Fla., Feb. 16, 2012   GeneLink ... biotech company, has completed the sale of the ... Life Sciences, Inc. (GeneWize)  to Capsalus Corp. (OTCBB: ... and wellness marketplace.  As previously disclosed, GeneLink and ...
... -- FirstMark today announced the completion of the clinical ... These clinical results demonstrate the extraordinary effectiveness of the ... myocardial infarction and death in patients with suspected or ... final data was well received in an oral presentation, ...
Cached Biology Technology:Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 2Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 3GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2FirstMark's Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI 2
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/7/2015)... July 7, 2015  Based on its recent ... Sullivan recognizes Credence ID, LLC with the 2015 ... of the Year Award. Credence ID has developed ... its mission of offering enrollment and identification solutions ... Credence ID was formed by experts from the ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... one way to get children to eat more whole grains, ... Federal nutrition guidelines recommend at least three servings a day ... typically only eat about one serving per day, largely because ... In this study, researchers served graham snacks with four ...
... EAST LANSING, Mich. A Michigan State University researcher ... parkin may help nerve cells fight off damage from ... therapies for the degenerative ailment. John Goudreau, an ... Unit, believes parkin can rescue certain neurons from injury ...
... programmed cell death, is essential to normal development, ... process dramatically transforms cellular structures but the limitations ... this structural reorganization a mystery. , Now, in ... issue of Proceedings of the National Academy ...
Cached Biology News:Specific protein may help neurons fix themselves in Parkinson's patients 2How do cells die? Biophotonic tools reveal real-time dynamics in living color 2How do cells die? Biophotonic tools reveal real-time dynamics in living color 3
XEDAR Antibody...
Pharmalyte, narrow range pH 4.2-4.9, 25 ml. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Immobiline for IEF and Carrier Ampholytes....
...
...
Biology Products: